Our last free report was on Aerie Pharmaceuticals (AERI). We managed to “catch lightning in a bottle” on that one as the shares have more than doubled since that report debuted thanks primarily to some very favorable Phase III trial results on a primary drug candidate. This type of immediate happens very rarely and we hope many of our subscribers to bretjenseninvests.com caught that rocket.
Our next biotech recommendation is focused on a completely different disease area than Aerie which was an ocular concern. However, it does share some common traits with that big winner. Analysts believe the stock has major upside based on current price targets. In addition, it also has seen recent insider buying and also has upcoming potential catalysts.